SCHEMBL6005103

SCHEMBL6005103

CCOC(=O)Nc1ccc(C=O)cc1Br

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.54
MAPT P10636 4/20 0.49
NLRP3 Q96P20 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 3/20 0.44
ALDH1A3 P47895 2/20 0.43
POLB P06746 1/20 0.43
F2R P25116 1/20 0.43
RAB9A P51151 2/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPC1 O15118 1/20 0.42
KMT2A Q03164 1/20 0.42
TP53 P04637 1/20 0.42
ALDH3A1 P30838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6005086 0.85 SMN1; SMN2 (0.69) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT
SCHEMBL11642079 0.83 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT
SCHEMBL6004780 0.83 CYP1A2 (0.55) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT
SCHEMBL6004303 0.83 CYP1A2 (0.55) CYP1A2CYP2C9CYP2C19SMN1; SMN2NLRP3
SCHEMBL18002664 0.80 NPC1 (0.45) SMN1; SMN2MAPTALDH1A3POLBRAB9A
SCHEMBL10753431 0.79 CYP1A2 (0.58) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT
SCHEMBL11722034 0.79 CYP1A2 (0.58) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT
SCHEMBL6004914 0.79 ALDH1A1 (0.54) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT
SCHEMBL7061559 0.79 CA1 (0.55) SMN1; SMN2MAPTALDH1A1HPGDALDH1A3
SCHEMBL12848306 0.78 CYP1A2 (0.56) CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060167087-A1 Substituted aniline derivatives H. LUNDBECK A/S (DK) 2006-07-27 US disclosed
EP-1606247-A1 SUBSTITUTED ANILINE DERIVATIVES H. Lundbeck A/S (DK) 2005-12-21 EP disclosed
WO-2004080950-A1 SUBSTITUTED ANILINE DERIVATIVES H. LUNDBECK A/S (DK) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167087-A1 Substituted aniline derivatives CYP3A43, UGT2B7, CYP3A7 CYP1A2 9/4885CYP2C9 12/4885CYP2C19 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.